Metabolic dysfunction-associated steatotic liver disease in women with polycystic ovary syndrome and its relation with other concomitant factors

Abstract

Background & Aims

Metabolic dysfunction-associated steatotic liver disease (MASLD) has an increasing prevalence in patients with polycystic ovary syndrome (PCOS). The purpose of this cross-sectional study was to assess MASLD status and the potential associated factors for MASLD in women with PCOS.

Methods

A total of 68 female subjects with PCOS, between the ages of 18 to 38 years, were recruited to this cross-sectional study. PCOS was diagnosed according to the revised 2003 Rotterdam Consensus as the presence of at least two of the following three criteria: (i) oligomenorrhoea or anovulation; (ii) clinical and/or biochemical signs of hyperandrogenaemia and (iii) polycystic ovaries on ultrasound. Fasting plasma glucose, insulin, lipid profile, and liver function tests were assessed. Body weight and composition were assessed using bioelectrical impedance analysis. Abdominal ultrasonography was administered for MASLD diagnosis.

Results

A total of 35 subjects (48.5%) were diagnosed with MASLD. Mean body mass index (34.9 ± 5.46 vs. 28.9 ± 5.13 kg/m², p < 0.001), body fat (46.9 ± 5.32 vs. 40.7 ± 6.77%, p < 0.001), Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) (4.0 ± 1.88 vs. 2.1 ± 1.01, p < 0.001), triglycerides (147.1 ± 84.34 vs. 102.5 ± 57.11 mg/dL, p = 0.010) and liver function markers were significantly higher in subjects with MASLD.

Conclusion

This study identifies key metabolic factors associated with the development of MASLD in women with PCOS. Specifically, insulin resistance, high body fat, waist/hip ratio, triglyceride levels, lower high-density lipoprotein (HDL) levels, and smoking were found to be associated with MASLD in this population. While these parameters are recognized as risk factors for MAFLD in general, their role in the PCOS population may differ due to the unique metabolic and hormonal profile of these women. These findings highlight the importance of monitoring and managing metabolic dysfunctions in PCOS patients to mitigate the risk of MASLD, offering valuable insights for clinical management and future research.

Keywords

Polycystic ovary syndrome metabolic dysfunction-associated steatotic liver disease obesity insulin resistance

Get full access to this article

View all access options for this article.

References

Wolf

Wattick

Kinkade

, et al. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health 2018; 15: 2589.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25.

Azziz

Carmina

Dewailly

, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237–4245.

Macut

Bjekic-Macut

Livadas

, et al. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Curr Pharm Des 2018; 24: 4593–4597.

Asfari

Sarmini

Baidoun

, et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol 2020; 7: e000352.

Jamialahmadi

Mancina

Ciociola

, et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology 2021; 160: 1634–1646.e7.

Vassilatou

. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20: 8351–8363.

Marino

Jornayvaz

. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21: 11053–11076.

Kempegowda

Melson

Manolopoulos

, et al. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab 2020; 11: 2042018820934319.

10.

Bozdag

Mumusoglu

Zengin

, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016; 31: 2841–2855.

11.

Sanchez-Garrido

Tena-Sempere

. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 2020; 35: 100937.

12.

Paschou

Polyzos

Anagnostis

, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020; 67: 1–8.

13.

Gayoso-Diz

Otero-Gonzalez

Rodriguez-Alvarez

, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013; 13: 47.

14.

Brunt

Kleiner

Wilson

, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–820.

15.

Schofield

. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 1985; 39: 5–41.

16.

Nishida

Kumanyika

. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and Waist-hip ratio. Eur J Clin Nutr 2010; 64: 2–5.

17.

Gallagher

Heymsfield

Heo

, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72: 694–701.

18.

Sarkar

Terrault

Duwaerts

, et al. The association of Hispanic ethnicity with nonalcoholic fatty liver disease in polycystic ovary syndrome. Curr Opin Gynecol Obstet 2018; 1: 24–33.

19.

Zhu

Jiang

, et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med 2013; 11: 725–732.

20.

Takahashi

Fukusato

. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 15539–15548.

21.

Ranathunga

Athukorala

Sumanatilleke

, et al. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. BMC Endocr Disord 2022; 22: 289.

22.

Apaydin

Kazan

Beysel

, et al.

The novel predictor of metabolic risk in patients with polycystic ovary syndrome: could it be the visceral adiposity index?

Eur Rev Med Pharmacol Sci 2022; 26: 7182–7187.

23.

Lewandowska

Wieckowska

Sajdak

, et al. Pre-pregnancy obesity vs. other risk factors in probability models of preeclampsia and gestational hypertension. Nutrients 2020; 12: 2681.

24.

Cavalcante

Sarno

Peixoto

, et al. Obesity and recurrent miscarriage: a systematic review and meta-analysis. J Obstet Gynaecol Res 2019; 45: 30–38.

25.

Zhao

, et al. Metabolic characteristics of normal weight central obesity phenotype polycystic ovary syndrome women: a large-scale national epidemiological survey. Reprod Biomed Online 2018; 37: 498–504.

26.

Kakoly

Khomami

Joham

, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update 2018; 24: 455–467.

27.

Gastaldelli

. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci 2017; 131: 2701–2704.

28.

Won

Seo

Yun

, et al. Non-alcoholic fatty liver disease in polycystic ovary syndrome women. Sci Rep 2021; 11: 7085.

29.

Zeng

Xie

Liu

, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 2020; 502: 214–221.

30.

Harsha Varma

Tirupati

Pradeep

TVS

, et al. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Diabetes Metab Syndr 2019; 13: 1065–1069.